Study identifier:D5890L00011
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A comparison of Symbicort Single inhaler Therapy (Symbicort Turbuhaler 160/4.5 µg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adults - a 26-week, randomised, open-label, parallel-group, multicentre study
asthma
Phase 3
No
-
All
1600
Interventional
18 Years +
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|